Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma

NCT02742727 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT02742727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02742727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2016
Completion date
March 31, 2018
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, angioimmunoblastic t-cell lymphoma, enteropathy-type intestinal t-cell lymphoma, extranodal nk/t-cell lymphoma, nasal type, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, nos, precursor t-cell lymphoblastic leukemia-lymphoma, t-cell large granular lymphocytic leukemia, t-cell prolymphocytic leukemia